{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:19:29Z","timestamp":1791299969533,"version":"4.1.0"},"reference-count":42,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2019.11895","type":"journal-article","created":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T15:30:49Z","timestamp":1568993449000},"page":"e1911895","source":"Crossref","is-referenced-by-count":59,"title":["Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non\u2013Small Cell Lung Cancer"],"prefix":"10.1001","volume":"2","author":[{"given":"Yu","family":"Chen","sequence":"first","affiliation":[{"name":"Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China"},{"name":"Cancer Bio-immunotherapy Center, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fuzhou, China"},{"name":"Department of Medical Oncology, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[{"name":"Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China"},{"name":"Department of Pathology, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[{"name":"Geneplus-Beijing Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ying","family":"Huang","sequence":"additional","affiliation":[{"name":"Fujian Medical University Cancer Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[{"name":"Fujian Medical University Cancer Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lin","sequence":"additional","affiliation":[{"name":"Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China"},{"name":"Cancer Bio-immunotherapy Center, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fuzhou, China"},{"name":"Department of Medical Oncology, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Zhu","family":"Chen","sequence":"additional","affiliation":[{"name":"Cancer Bio-immunotherapy Center, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fuzhou, China"},{"name":"Department of Medical Oncology, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Ping","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Qi","family":"Wang","sequence":"additional","affiliation":[{"name":"Geneplus-Beijing Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Xi","family":"Wang","sequence":"additional","affiliation":[{"name":"Geneplus-Beijing Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leong Kin","family":"Pan","sequence":"additional","affiliation":[{"name":"China Certification and Inspection Group, Kuok Kim Medical Center III, Macao, China"},{"name":"Hui Xian Medical Center, Macao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Feng","family":"Xia","sequence":"additional","affiliation":[{"name":"Geneplus-Beijing Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yi","sequence":"additional","affiliation":[{"name":"Geneplus-Beijing Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-Ben","family":"Chen","sequence":"additional","affiliation":[{"name":"Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China"},{"name":"Cancer Bio-immunotherapy Center, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fuzhou, China"},{"name":"Department of Radiation Oncology, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong-Wei","family":"Zheng","sequence":"additional","affiliation":[{"name":"Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China"},{"name":"Department of Pathology, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeng-Qing","family":"Guo","sequence":"additional","affiliation":[{"name":"Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China"},{"name":"Cancer Bio-immunotherapy Center, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fuzhou, China"},{"name":"Department of Medical Oncology, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Ji","family":"Pan","sequence":"additional","affiliation":[{"name":"Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou, China"},{"name":"Cancer Bio-immunotherapy Center, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fuzhou, China"},{"name":"Department of Radiation Oncology, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2019,9,20]]},"reference":[{"issue":"19","key":"zoi190455r1","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer.","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"25","key":"zoi190455r2","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer.","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med"},{"issue":"10027","key":"zoi190455r3","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"issue":"10030","key":"zoi190455r4","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"issue":"17","key":"zoi190455r5","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi190455r6","doi-asserted-by":"publisher","first-page":"OF1","DOI":"10.1158\/2159-8290.CD-NB2015-042","article-title":"Nivolumab approved for lung cancer.","volume":"5","year":"2015","journal-title":"Cancer Discov"},{"issue":"11","key":"zoi190455r7","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"zoi190455r8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol"},{"issue":"9","key":"zoi190455r9","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/jamaoncol.2016.0639","article-title":"Biomarkers for the clinical use of PD-1\/PD-L1 inhibitors in non-small-cell lung cancer: a review.","volume":"2","author":"Sacher","year":"2016","journal-title":"JAMA Oncol"},{"issue":"12","key":"zoi190455r10","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1200\/JCO.18.01042","article-title":"First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers.","volume":"37","author":"Ready","year":"2019","journal-title":"J Clin Oncol"},{"issue":"22","key":"zoi190455r11","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden.","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi190455r12","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1158\/2159-8290.CD-17-0226","article-title":"DNA damage and repair biomarkers of immunotherapy response.","volume":"7","author":"Mouw","year":"2017","journal-title":"Cancer Discov"},{"issue":"7","key":"zoi190455r13","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1158\/2159-8290.CD-16-0908","article-title":"Identification of a DNA damage-induced alternative splicing pathway that regulates p53 and cellular senescence markers.","volume":"7","author":"Chen","year":"2017","journal-title":"Cancer Discov"},{"issue":"17","key":"zoi190455r14","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1038\/sj.onc.1210885","article-title":"The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1\/BRCA2-deficient and ER\/PR\/ERBB2-triple-negative breast cancer.","volume":"27","author":"Tommiska","year":"2008","journal-title":"Oncogene"},{"issue":"2","key":"zoi190455r15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the Cancer Genome Atlas.","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"issue":"5","key":"zoi190455r16","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.molcel.2018.08.013","article-title":"A systematic p53 mutation library links differential functional impact to cancer mutation pattern and evolutionary conservation.","volume":"71","author":"Kotler","year":"2018","journal-title":"Mol Cell"},{"issue":"1","key":"zoi190455r17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/humu.v30:1","article-title":"Functional and computational assessment of missense variants in the ataxia-telangiectasia mutated (ATM) gene: mutations with increased cancer risk.","volume":"30","author":"Mitui","year":"2009","journal-title":"Hum Mutat"},{"key":"zoi190455r18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.dnarep.2014.01.010","article-title":"Functional overlaps between XLF and the ATM-dependent DNA double strand break response.","volume":"16","author":"Kumar","year":"2014","journal-title":"DNA Repair (Amst)"},{"issue":"5","key":"zoi190455r19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"10066","key":"zoi190455r20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"issue":"20","key":"zoi190455r21","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"zoi190455r23","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types.","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"issue":"4","key":"zoi190455r24","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","article-title":"Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.","volume":"39","author":"Bindea","year":"2013","journal-title":"Immunity"},{"issue":"11","key":"zoi190455r25","doi-asserted-by":"publisher","first-page":"e1356145","DOI":"10.1080\/2162402X.2017.1356145","article-title":"EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer.","volume":"6","author":"Dong","year":"2017","journal-title":"Oncoimmunology"},{"issue":"18","key":"zoi190455r26","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis.","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"6","key":"zoi190455r27","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in context.","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"issue":"5","key":"zoi190455r28","doi-asserted-by":"publisher","first-page":"a026070","DOI":"10.1101\/cshperspect.a026070","article-title":"p53 in the DNA-damage-repair process.","volume":"6","author":"Williams","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"10","key":"zoi190455r29","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/ng.2762","article-title":"Emerging landscape of oncogenic signatures across human cancers.","volume":"45","author":"Ciriello","year":"2013","journal-title":"Nat Genet"},{"issue":"36","key":"zoi190455r30","doi-asserted-by":"publisher","first-page":"4524","DOI":"10.1200\/JCO.2011.41.0852","article-title":"Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.","volume":"30","author":"Skowronska","year":"2012","journal-title":"J Clin Oncol"},{"issue":"7216","key":"zoi190455r31","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nature07423","article-title":"Somatic mutations affect key pathways in lung adenocarcinoma.","volume":"455","author":"Ding","year":"2008","journal-title":"Nature"},{"issue":"16","key":"zoi190455r32","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1101\/gad.1815309","article-title":"The combined status of ATM and p53 link tumor development with therapeutic response.","volume":"23","author":"Jiang","year":"2009","journal-title":"Genes Dev"},{"issue":"21","key":"zoi190455r33","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1038\/emboj.2009.276","article-title":"ATM and Artemis promote homologous recombination of radiation-induced DNA double-strand breaks in G2.","volume":"28","author":"Beucher","year":"2009","journal-title":"EMBO J"},{"issue":"1","key":"zoi190455r34","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1038\/ncomms4347","article-title":"ATM specifically mediates repair of double-strand breaks with blocked DNA ends.","volume":"5","author":"\u00c1lvarez-Quil\u00f3n","year":"2014","journal-title":"Nat Commun"},{"issue":"6","key":"zoi190455r35","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response.","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol Cell"},{"issue":"10","key":"zoi190455r36","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.dnarep.2008.06.018","article-title":"Comparison of nonhomologous end joining and homologous recombination in human cells.","volume":"7","author":"Mao","year":"2008","journal-title":"DNA Repair (Amst)"},{"issue":"1","key":"zoi190455r37","first-page":"22","article-title":"Role of DNA-dependent protein kinase catalytic subunit in cancer development and treatment.","volume":"1","author":"Hsu","year":"2012","journal-title":"Transl Cancer Res"},{"issue":"6","key":"zoi190455r38","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41568-019-0143-7","article-title":"The broken cycle: E2F dysfunction in\u00a0cancer.","volume":"19","author":"Kent","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"7510","key":"zoi190455r39","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/nature13537","article-title":"Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis.","volume":"511","author":"Sab\u00f2","year":"2014","journal-title":"Nature"},{"issue":"12","key":"zoi190455r40","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nrc3627","article-title":"VEGF targets the tumour cell.","volume":"13","author":"Goel","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"18","key":"zoi190455r41","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.1158\/1078-0432.CCR-16-1401","article-title":"PD-1 axis inhibitors in EGFR- and ALK-driven lung cancer: lost cause?","volume":"22","author":"Gettinger","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"zoi190455r42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/PPO.0000000000000303","article-title":"Mechanisms of resistance to PD-1 and PD-L1 blockade.","volume":"24","author":"Nowicki","year":"2018","journal-title":"Cancer J"},{"key":"zoi190455r22","unstructured":"Broad Institute. Genomic Data Analysis Center. https:\/\/gdac.broadinstitute.org\/. Accessed August 12, 2019."}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2751557\/chen_2019_oi_190455.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T15:30:52Z","timestamp":1568993452000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2751557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,20]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.11895","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,20]]}}}